Cardiometabolic DiseasesDEBATENCT06426082
Deciphering a Novel and Unique Brown Adipose Tissue Depot in Women
A study testing Thermoneutral condition, Cold condition and Aerobic exercise condition in people with Cardiometabolic Diseases, run by Universidad de Almeria at 1 site in Spain.
Trial summary
Type of Study: Clinical Trial Goal: The goal of this clinical trial is to investigate specific brown and beige fat cells in the dorsocervical area of young, lean adult women. Participant Population/Health Conditions: The study will involve 40 young, lean adult women. Read more about this study
- Who is it for?
- Ages 18 to 22 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Cardiometabolic Diseases
- What is being tested?
- Thermoneutral condition, Cold condition and Aerobic exercise condition
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteSpain
- Study dates
- 1 Nov 2024to Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 22 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- 18-22 years of age women.
- BMI between ≥18 and <25 kg/m2
- Are willing to be randomized to either of these 4 groups.
- Must be sedentary (i.e., do not perform exercise or go to the gym).
- Participants should have regular menstrual cycles.
- Must be willing to adhere to all study procedures, including attendance at all study visits.
- Must be willing to have biological samples stored for future research.
- Must accept the use of the Period Calendar and Google Fit Apps on their mobile phones.
Who cannot join
- Diabetes mellitus (determined based on fasting glucose levels defined by ADA criteria).
- Any other active endocrine disease (thyroid disease, any signs of Cushing's syndrome, adrenal disease and lipid-associated disorders such as familial hypercholesterolemia).
- Any cardiac disease (i.e., ischemic cardiac disease, arrhythmias, severe heart failure).
- Use of medication known to influence glucose and/or lipid metabolism or brown fat activity (e.g., beta-blockers, antidepressants, corticosteroids).
- Use of medication shown to increase risk of hypokalemia after salbutamol administration (e.g., xanthine derivatives, steroids and diuretics).
- Clinically relevant abnormalities in clinical chemistry or electrocardiogram (ECG) at screening (to be judged by the study physician).
Show all 15Show fewer
- A first-degree family member with sudden cardiac death.
- Any chronic renal or hepatic disease.
- Any other contra-indications for the use of salbutamol or propranolol.
- Abuse of alcohol or other substances.
- Smoking.
- Current participation in another research projects that may influence the current research project.
- Use of beta-adrenergic receptor agonists (e.g., asthma).
- Polycystic ovary syndrome.
- Diagnosed psychotic conditions.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Deciphering the Molecular and Secretory Functions of a Novel and Unique Brown Adipose Tissue Depot in Women
Type of Study: Clinical Trial
Goal: The goal of this clinical trial is to investigate specific brown and beige fat cells in the dorsocervical area of young, lean adult women.
Read more
Participant Population/Health Conditions: The study will involve 40 young, lean adult women.
Main Questions: The main questions this study aims to answer are:
- Are there active brown or beige adipocytes in the subcutaneous fat of the dorsocervical area (i.e., iBAT)?
- What is the secretory function of these adipocytes?
- How do traditional interventions like cold exposure, as well as new approaches like Beta-2 agonist stimulation and exercise, affect the thermogenesis of these fat cells at the cellular and molecular levels?
Participants Will:
Be randomized into one of four groups: thermoneutral exposure, cold exposure, aerobic exercise, or Beta-2 agonist treatment.
Follow their assigned regimen for 4 weeks. Provide tissue samples from the dorsocervical area and abdomen before and after the 4-week intervention.
Undergo analysis of these samples using advanced techniques to understand the presence and activity of brown and beige fat cells.
Comparison Group: Researchers will compare the effects of different interventions (thermoneutral exposure, cold exposure, aerobic exercise, Beta-2 agonist treatment) on the presence and thermogenesis of brown and beige fat cells in the dorsocervical area.
Read the detailed description
Cardiometabolic diseases affect almost 50% of the population in the Western World. While lifestyle plus pharmacological interventions may provide short-term benefits, more research is needed to understand the long-term effectiveness and underlying molecular mechanisms. Brown adipose tissue (BAT) is a thermogenic tissue that combusts large amounts of glucose and lipids to generate heat and secretes signalling molecules known as 'batokines' that can influence cardiometabolic health. Previous research has shown that BAT is active in adults, primarily in the supraclavicular region, as demonstrated by the uptake of 18F-Fluorodeoxyglucose. Recently, it has been demonstrated that a rare subpopulation of brown adipocytes increases their abundance at higher temperatures and can regulate the thermogenesis of neighbouring adipocytes. Thus, it is plausible that classical (e.g., cold exposure) and novel interventions (i.e., Beta-2 stimulation and exercise) that can activate BAT, would induce a remodelling in the brown/beige subpopulation adipocytes that govern whole tissue thermogenesis. These unstudied changes in human BAT physiology could potentially explain how BAT activation could enhance cardiometabolic health. However, despite over a decade of research, our understanding of the role of BAT in human physiology in humans is limited. This lack of knowledge may be mainly explained because i) obtaining biological samples of human BAT is very difficult and ii) the seasonal variation strongly influences the current gold standard (PET-CT scan). Given the pilot data found in this proposal, young, lean adult women may have a novel and undescribed thermogenic active BAT depot at the dorsocervical area (i.e., interscapular BAT=iBAT).
Based on that, the main hypothesis is that there are brown and/or beige adipocytes present within the subcutaneous adipose tissue of the dorsocervical area (i.e., iBAT) that have a unique composition of adipocyte subpopulations and specific secretory functions. Additionally, the specific subpopulations of brown and/or beige adipocytes related to thermogenesis in iBAT can be increased through exposure to cold temperatures, Beta-2 agonist stimulation, and exercise in young, lean women.
Thus, the main objective of this study is to investigate whether the subcutaneous fat in the dorsocervical area contains active brown and/or beige adipocytes (i.e., iBAT), understand its secretory function, and study the impact of traditional (e.g. cold exposure) and new interventions (e.g. Beta-2 agonist and exercise) on iBAT thermogenesis at the cellular and molecular levels.
Thus, the DEBATE project will carry out a randomized controlled trial where 40 young, lean adult women will be randomized into a thermoneutral exposure group (2 hours/day at 32ºC; 5 days/week) or a cold exposure group (2 hours/day at 18ºC; 5 days/week) or an aerobic exercise group (5 days/week at 65% heart rate reserve for 60 minutes) or a Beta-2 agonist group (salbutamol 12 mg/day. 7 days week). Before and after the 4-week intervention, iBAT tissue samples from the dorsocervical area and subcutaneous white adipose tissue (scWAT) from the abdomen will be collected. In these biological samples, the investigators will apply a set of cutting-edge omics (e.g., single nucleus RNA-seq) that will allow us to investigate whether iBAT is present and metabolically active in adults. The investigators will also conduct a set of in vitro experiments to discover the secretory function of this novel depot.
- Conditions
- Cardiometabolic Diseases
- Being tested
- Thermoneutral condition, Cold condition, Aerobic exercise condition, Salbutamol
- Keywords
- brown adipose tissue, cold exposure, hot exposure, dorsocervical fat, exercise
- Medical subject headings
- Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Thermoneutral conditionBehavioural
Participants will be exposed 2 hours/day at 32ºC for 5 days/week
Cold conditionBehavioural
Participants will be exposed 2 hours/day at 18ºC for 5 days/week
Aerobic exercise conditionBehavioural
Participants will perform aerobic exercise training 5 days/week at 65% heart rate reserve for 60 minutes each training session
SalbutamolDrug
Participants will take salbutamol 12 mg/day. 7 days week
| Study group | Role | What they receive |
|---|---|---|
| Thermoneutral condition | Placebo comparator | n=10; receiving a thermoneutral exposure 2 hours/day at 32ºC; 5 days/week; Total 4 weeks Receives: Behavioral: Thermoneutral condition |
| Cold condition | Experimental | n=10; receiving 2 hours/day at 18ºC; 5 days/week; Total 4 weeks Receives: Behavioral: Cold condition |
| Salbutamol | Experimental | n=10; salbutamol 12 mg/day. 7 days week. Total 4 weeks Receives: Drug: Salbutamol |
| Aerobic exercise | Experimental | n=10; receiving 5 days/week at 65% heart rate reserve for 60 minutes each training session. Total 4 weeks Receives: Behavioral: Aerobic exercise condition |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in UCP1 expression in the dorsocervical area
Investigators will quantify the level UCP1 expression by qPCR in white adipose tissue biopsies obtained before and after the intervention
Measured: 2 years
Secondary outcomes (8)
Body composition (BIA, Tanita)
Change in fat percentage (% of fat)
Measured: 2 years
Cardiorespiratory fitness test (indirect calorimetry and monarch bike)
Change in VO2max (ml/kg/min)
Measured: 2 years
LDL quantification in blood
Change in LDL-C (mg/dL)
Measured: 2 years
HDL quantification in blood
Change in HDL-C (mg/dL)
Measured: 2 years
Glucose quantification in blood
Change in Glucose (mg/dL)
Measured: 2 years
Insulin quantification in blood
Change in Insulin (µIU/mL)
Measured: 2 years
Triglycerides quantification in blood
Change in Triglycerides (mg/dL)
Measured: 2 years
C-reactive protein quantification in blood
Change in CRP (mg/L)
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 May 2024
- Study start1 Nov 2024 (estimated)
- Primary completion31 Aug 2025 (estimated)
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cardiometabolic DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study will consist of a randomized controlled trial in which forty young, lean women will be assigned to a control group (n=10; receiving a thermoneutral exposure 2 hours/day at 32ºC; 5 days/week) or a cold exposure group (n=10; receiving 2 hours/day at 18ºC; 5 days/week) or aerobic exercise group (n=10; receiving 5 days/week at 65% heart rate reserve for 60 minutes each training session) or an ADBR2 agonist ingestion (n=10; salbutamol 12 mg/day. 7 days week).
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidad de Almeria
- Sponsor type
- University, hospital or other
- Collaborators
- Leiden University Medical Center, ETH Zurich (Switzerland)
- Responsible party
- Principal investigator, Borja Martínez Tellez, Universidad de Almeria
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06426082
- Sponsor's protocol ID
- PID2022-141442OA-I00
- Acronym
- DEBATE
- Status last verified
- May 2024
- First submitted
- 11 Oct 2023
- Last updated
- 23 May 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Martinez-Tellez B, Sanchez-Delgado G, Alcantara JMA, Acosta FM, Amaro-Gahete FJ, Osuna-Prieto FJ, Perez-Bey A, Jimenez-Pavon D, Llamas-Elvira JM, Gil A, Aguilera CM, Rensen PCN, Ruiz JR. Evidence of high 18 F-fluorodeoxyglucose uptake in the subcutaneous adipose tissue of the dorsocervical area in young adults. Exp Physiol. 2019 Feb;104(2):168-173. doi: 10.1113/EP087428. Epub 2018 Dec 18.
PubMed 30468689
Study at a glance
From the registry record, last updated by the sponsor on 23 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Deciphering the Molecular and Secretory Functions of a Novel and Unique Brown Adipose Tissue Depot in Women
- ClinicalTrials.gov ID
- NCT06426082
- Acronym / sponsor ID
- DEBATE / PID2022-141442OA-I00
- Conditions
- Cardiometabolic Diseases
- Keywords
- brown adipose tissue, cold exposure, hot exposure, dorsocervical fat, exercise
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Universidad de AlmeriaUniversity, hospital or other
- Collaborators
- Leiden University Medical Center, ETH Zurich (Switzerland)
- Study start
- 1 Nov 2024 (estimated)
- Primary completion
- 31 Aug 2025 (estimated)
- Study completion
- Aug 2026 (estimated)
- First posted
- 23 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Type of Study: Clinical Trial
Goal: The goal of this clinical trial is to investigate specific brown and beige fat cells in the dorsocervical area of young, lean adult women.
Participant Population/Health Conditions: The study will involve 40 young, lean adult women.
Main Questions: The main questions this study aims to answer are:
- Are there active brown or beige adipocytes in the subcutaneous fat of the dorsocervical area (i.e., iBAT)?
- What is the secretory function of these adipocytes?
- How do traditional interventions like cold exposure, as well as new approaches like Beta-2 agonist stimulation and exercise, affect the thermogenesis of these fat cells at the cellular and molecular levels?
Participants Will:
Be randomized into one of four groups: thermoneutral exposure, cold exposure, aerobic exercise, or Beta-2 agonist treatment.
Follow their assigned regimen for 4 weeks. Provide tissue samples from the dorsocervical area and abdomen before and after the 4-week intervention.
Undergo analysis of these samples using advanced techniques to understand the presence and activity of brown and beige fat cells.
Comparison Group: Researchers will compare the effects of different interventions (thermoneutral exposure, cold exposure, aerobic exercise, Beta-2 agonist treatment) on the presence and thermogenesis of brown and beige fat cells in the dorsocervical area.
Detailed description
Cardiometabolic diseases affect almost 50% of the population in the Western World. While lifestyle plus pharmacological interventions may provide short-term benefits, more research is needed to understand the long-term effectiveness and underlying molecular mechanisms. Brown adipose tissue (BAT) is a thermogenic tissue that combusts large amounts of glucose and lipids to generate heat and secretes signalling molecules known as 'batokines' that can influence cardiometabolic health. Previous research has shown that BAT is active in adults, primarily in the supraclavicular region, as demonstrated by the uptake of 18F-Fluorodeoxyglucose. Recently, it has been demonstrated that a rare subpopulation of brown adipocytes increases their abundance at higher temperatures and can regulate the thermogenesis of neighbouring adipocytes. Thus, it is plausible that classical (e.g., cold exposure) and novel interventions (i.e., Beta-2 stimulation and exercise) that can activate BAT, would induce a remodelling in the brown/beige subpopulation adipocytes that govern whole tissue thermogenesis. These unstudied changes in human BAT physiology could potentially explain how BAT activation could enhance cardiometabolic health. However, despite over a decade of research, our understanding of the role of BAT in human physiology in humans is limited. This lack of knowledge may be mainly explained because i) obtaining biological samples of human BAT is very difficult and ii) the seasonal variation strongly influences the current gold standard (PET-CT scan). Given the pilot data found in this proposal, young, lean adult women may have a novel and undescribed thermogenic active BAT depot at the dorsocervical area (i.e., interscapular BAT=iBAT).
Based on that, the main hypothesis is that there are brown and/or beige adipocytes present within the subcutaneous adipose tissue of the dorsocervical area (i.e., iBAT) that have a unique composition of adipocyte subpopulations and specific secretory functions. Additionally, the specific subpopulations of brown and/or beige adipocytes related to thermogenesis in iBAT can be increased through exposure to cold temperatures, Beta-2 agonist stimulation, and exercise in young, lean women.
Thus, the main objective of this study is to investigate whether the subcutaneous fat in the dorsocervical area contains active brown and/or beige adipocytes (i.e., iBAT), understand its secretory function, and study the impact of traditional (e.g. cold exposure) and new interventions (e.g. Beta-2 agonist and exercise) on iBAT thermogenesis at the cellular and molecular levels.
Thus, the DEBATE project will carry out a randomized controlled trial where 40 young, lean adult women will be randomized into a thermoneutral exposure group (2 hours/day at 32ºC; 5 days/week) or a cold exposure group (2 hours/day at 18ºC; 5 days/week) or an aerobic exercise group (5 days/week at 65% heart rate reserve for 60 minutes) or a Beta-2 agonist group (salbutamol 12 mg/day. 7 days week). Before and after the 4-week intervention, iBAT tissue samples from the dorsocervical area and subcutaneous white adipose tissue (scWAT) from the abdomen will be collected. In these biological samples, the investigators will apply a set of cutting-edge omics (e.g., single nucleus RNA-seq) that will allow us to investigate whether iBAT is present and metabolically active in adults. The investigators will also conduct a set of in vitro experiments to discover the secretory function of this novel depot.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 4
- Model description
- This study will consist of a randomized controlled trial in which forty young, lean women will be assigned to a control group (n=10; receiving a thermoneutral exposure 2 hours/day at 32ºC; 5 days/week) or a cold exposure group (n=10; receiving 2 hours/day at 18ºC; 5 days/week) or aerobic exercise group (n=10; receiving 5 days/week at 65% heart rate reserve for 60 minutes each training session) or an ADBR2 agonist ingestion (n=10; salbutamol 12 mg/day. 7 days week).
| Arm | Type | Receives |
|---|---|---|
| Thermoneutral condition | Placebo comparator | Behavioral: Thermoneutral conditionn=10; receiving a thermoneutral exposure 2 hours/day at 32ºC; 5 days/week; Total 4 weeks |
| Cold condition | Experimental | Behavioral: Cold conditionn=10; receiving 2 hours/day at 18ºC; 5 days/week; Total 4 weeks |
| Salbutamol | Experimental | Drug: Salbutamoln=10; salbutamol 12 mg/day. 7 days week. Total 4 weeks |
| Aerobic exercise | Experimental | Behavioral: Aerobic exercise conditionn=10; receiving 5 days/week at 65% heart rate reserve for 60 minutes each training session. Total 4 weeks |
Who may qualify
- Ages
- 18 to 22 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- 18-22 years of age women.
- BMI between ≥18 and <25 kg/m2
- Are willing to be randomized to either of these 4 groups.
- Must be sedentary (i.e., do not perform exercise or go to the gym).
- Participants should have regular menstrual cycles.
Key exclusion criteria (15 listed)
- Diabetes mellitus (determined based on fasting glucose levels defined by ADA criteria).
- Any other active endocrine disease (thyroid disease, any signs of Cushing's syndrome, adrenal disease and lipid-associated disorders such as familial hypercholesterolemia).
- Any cardiac disease (i.e., ischemic cardiac disease, arrhythmias, severe heart failure).
- Use of medication known to influence glucose and/or lipid metabolism or brown fat activity (e.g., beta-blockers, antidepressants, corticosteroids).
- Use of medication shown to increase risk of hypokalemia after salbutamol administration (e.g., xanthine derivatives, steroids and diuretics).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Thermoneutral conditionParticipants will be exposed 2 hours/day at 32ºC for 5 days/week | Behavioural | Thermoneutral condition |
| Cold conditionParticipants will be exposed 2 hours/day at 18ºC for 5 days/week | Behavioural | Cold condition |
| Aerobic exercise conditionParticipants will perform aerobic exercise training 5 days/week at 65% heart rate reserve for 60 minutes each training session | Behavioural | Aerobic exercise |
| SalbutamolParticipants will take salbutamol 12 mg/day. 7 days week | Drug | Salbutamol |
Primary outcome
Change in UCP1 expression in the dorsocervical area
Time frame: 2 years
Investigators will quantify the level UCP1 expression by qPCR in white adipose tissue biopsies obtained before and after the intervention
8 secondary outcomes
Body composition (BIA, Tanita)
Time frame: 2 years
Cardiorespiratory fitness test (indirect calorimetry and monarch bike)
Time frame: 2 years
LDL quantification in blood
Time frame: 2 years
HDL quantification in blood
Time frame: 2 years
Glucose quantification in blood
Time frame: 2 years
Insulin quantification in blood
Time frame: 2 years
Triglycerides quantification in blood
Time frame: 2 years
C-reactive protein quantification in blood
Time frame: 2 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 May 2024.
- Background: PubMed 30468689Martinez-Tellez B, Sanchez-Delgado G, Alcantara JMA, Acosta FM, Amaro-Gahete FJ, Osuna-Prieto FJ, Perez-Bey A, Jimenez-Pavon D, Llamas-Elvira JM, Gil A, Aguilera CM, Rensen PCN, Ruiz JR. Evidence of high 18 F-fluorodeoxyglucose uptake in the subcutaneous adipose tissue of the dorsocervical area in young adults. Exp Physiol. 2019 Feb;104(2):168-173. doi: 10.1113/EP087428. Epub 2018 Dec 18.
- Individual participant dataSharing planned: Yes
Related trials for Cardiometabolic Diseases
Not yet recruitingObservational study
A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating ...
Cardiometabolic Risk Factors, Mental Health
RecruitingObservational study
Food-i-Sense Analytics: Integrating AI Into Continuous Glucose Monitoring Data Analysis for Precision Nutrition.
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Artificial Intelligence Mobile Application
Recruiting
Improving Sleep Health and Circadian Timing to Support Cardiometabolic Health in Adolescents
Overweight Adolescents, Sleep
RecruitingObservational study
Asprosin and miRNA Expression in Young Women With Metabolic Syndrome
Metabolic Syndrome, Insulin Resistance
Not yet recruiting
Multimodal AI-Driven Out-of-Hospital Management for Hypertension and Cardiometabolic Risk
Hypertension, Hyperglycemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Thermoneutral condition, Cold condition and Aerobic exercise condition in people with Cardiometabolic Diseases, run by Universidad de Almeria at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Borja Martinez Tellez, PhD (+34 950215334 ext. +34, borjammt@ual.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in UCP1 expression in the dorsocervical area (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06426082, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2024.